S3-E27.6 - 5th Global NASH Congress Wrap-Up: Dual Weight Loss Agonists, Expanded Imaging and the Implications for NAFLD

Send us Fan MailOn May 27 and 28, Surfing the NASH Tsunami covered the 5th Global NASH Congress, which discussed a wide range of NAFLD-related topics. This conversation includes two shorter interviews. In the first, Louise Campbell and Aged Diagnostics CEO Rachel Zayas interview Altimmune Chief Medical Officer Scott Harris about dual agonist weight loss agents. In the second, Rachel interviews Antaros Medical Vice President of Global Business Development Caleb Roberts about the increasing value of imaging in the study of Fatty Liver Disease.In the first interview, Scott Harris discusses the value of dual receptor agonists in weight loss. He focuses on existing published studies for GLP-1 agonist semaglutide and dual GLP-1/GIP agonist tirzepatide and shares some data on pemvidutide, Altimmune’s dual receptor GLP-1/glucagon agonist. The discussion branches into other issues, including the impact of rapid weight loss on micronutrients and the concept of sarcopenic obesity.In the second interview, Caleb Roberts discusses the relevance of imaging for researchers assessing the metabolic effects of NASH medications on the overall metabolic profile and perhaps other organ systems, notably the kidneys. He also discusses briefly some of the concepts that Antaros is developing, including PET tracers.